The molecular basis of von Hippel-Lindau disease.
Iliopoulos
O
O
Department of Medicine, Dana-Farber Cancer Institute, Boston, MA 02115, USA.
Kaelin
W G
WG
D015687:Cell Hypoxia; D000075065:Elongin; D016228:Endothelial Growth Factors; D016147:Genes, Tumor Suppressor; D006801:Humans; D008025:Ligases; D008222:Lymphokines; D011485:Protein Binding; D011506:Proteins / Q000235:genetics / Q000378:metabolism; D012333:RNA, Messenger; D014157:Transcription Factors / Q000378:metabolism; D025521:Tumor Suppressor Proteins; D044767:Ubiquitin-Protein Ligases; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors; D051794:Von Hippel-Lindau Tumor Suppressor Protein; D006623:von Hippel-Lindau Disease / Q000235:genetics*
D000075065:Elongin; D016228:Endothelial Growth Factors; D008222:Lymphokines; D011506:Proteins; D012333:RNA, Messenger; D014157:Transcription Factors; D025521:Tumor Suppressor Proteins; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors; D044767:Ubiquitin-Protein Ligases; D051794:Von Hippel-Lindau Tumor Suppressor Protein; D008025:Ligases; C497446:VHL protein, human